Ads
related to: fasenra asthma medication dosage information sheet- Administration Options
With FASENRA You May Have Options.
View At-Home & Self-Admin Info.
- See Approved Use
FASENRA May Help Treat Your
Condition, Find Out More.
- Access FAQ
See Answers To Your Questions About
Your Condition & The FASENRA Pen.
- FASENRA 360
Sign Up For Personalized Resources
For Your FASENRA Journey.
- Patient Resources
Find Support Resources You May Need
When Starting FASENRA.
- Considering FASENRA?
It May Be Time To Think Differently
About Your Treatment Options.
- Administration Options
Search results
Results From The WOW.Com Content Network
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor . It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca. [3] [4] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
This is because inhaling these drugs allows them to directly interact with your airways (as opposed to going into your bloodstream) while requiring a much smaller dosage and therefore potentially ...
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
Ads
related to: fasenra asthma medication dosage information sheet